2022
ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor
Singer DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. American Heart Journal 2022, 249: 76-85. PMID: 35472303, DOI: 10.1016/j.ahj.2022.04.005.Peer-Reviewed Original ResearchConceptsOral anticoagulant therapyEfficacy end pointSafety end pointUndiagnosed atrial fibrillationAtrial fibrillationEnd pointAF screeningLong-term oral anticoagulant therapyIndividuals age 70 yearsRate of strokeProportion of patientsScreen-detected casesNovel coronavirus disease 2019 (COVID-19) pandemicAge 70 yearsParoxysmal atrial fibrillationCoronavirus disease 2019 (COVID-19) pandemicPrimary care practicesTarget sample sizeDisease 2019 pandemicLong-term screeningElectronic health recordsBleeding outcomesScreening armAF burdenUsual care
2018
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Investigators S. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Journal Of Clinical Lipidology 2018, 12: 958-965. PMID: 29685591, DOI: 10.1016/j.jacl.2018.03.088.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedPlacebo EffectProportional Hazards ModelsProprotein Convertase 9Risk FactorsConceptsProprotein convertase subtilisin kexin type 9Major adverse cardiovascular eventsAdverse cardiovascular eventsPCSK9 inhibitionNon-FH patientsFH patientsCardiovascular eventsFamilial hypercholesterolemiaMean (SD) baseline LDL-C levelElevated low-density lipoprotein cholesterolFuture cardiovascular event ratesBaseline LDL-C levelsLow-density lipoprotein cholesterolSubtilisin kexin type 9Cardiovascular event reductionHard cardiovascular eventsHard cardiovascular outcomesPlacebo-controlled dataPrimary prevention patientsCardiovascular event ratesLDL-C reductionProportion of patientsClinical trial programLDL-C levelsIncidence rate ratios
2007
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal Of Medicine 2007, 357: 2109-2122. PMID: 17984165, DOI: 10.1056/nejmoa0706628.Peer-Reviewed Original ResearchConceptsMajor cardiovascular eventsRisk of deathCardiovascular eventsCholesteryl ester transfer proteinLipoprotein cholesterolFirst major cardiovascular eventHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolEffects of torcetrapibHigh cardiovascular riskNonfatal myocardial infarctionDouble-blind studySystolic blood pressureCoronary heart diseaseRisk of mortalityPlasma lipoprotein levelsEster transfer proteinCoronary eventsCardiac eventsCardiovascular riskUnstable anginaBlood pressurePrimary outcomeSerum potassiumLipoprotein levelsEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal Of Medicine 2007, 356: 1304-1316. PMID: 17387129, DOI: 10.1056/nejmoa070635.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticholesteremic AgentsAtorvastatinBlood PressureCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHumansMaleMiddle AgedProspective StudiesPyrrolesQuinolinesUltrasonography, InterventionalConceptsAtheroma volumeHDL cholesterolLDL cholesterolAtorvastatin monotherapyCoronary atherosclerosisLipoprotein cholesterolBlood pressureIntravascular ultrasonographyHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolEffects of torcetrapibCholesteryl ester transfer protein inhibitorsPercent atheroma volumeSystolic blood pressureHDL cholesterol levelsLack of efficacyCETP inhibitor torcetrapibMechanism of actionCardiovascular riskSmall favorable effectCholesterol levelsDisease progressionDiseased vessel segmentDrug classesSecondary measuresDesigns of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*
Kastelein JJ, van Leuven SI, Evans GW, Riley WA, Revkin JH, Shear CL, Bots ML. Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research And Opinion 2007, 23: 885-894. PMID: 17407645, DOI: 10.1185/030079907x182121.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlgorithmsAnticholesteremic AgentsAtherosclerosisAtorvastatinCarotid ArteriesClinical Trials as TopicDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHumansHyperlipidemia, Familial CombinedHyperlipoproteinemia Type IIMaleMiddle AgedModels, BiologicalPyrrolesQuinolinesResearch DesignTunica IntimaUltrasonographyConceptsCarotid intima-media thicknessMaximum carotid intima-media thicknessNCEP ATP III guidelinesATP III guidelinesCarotid ultrasound studiesDose of atorvastatinPrimary efficacy measureLDL-C levelsIntima-media thicknessHeterozygous familial hypercholesterolemiaEnd of studyB-mode ultrasonographyFurther outcome measuresRADIANCE studyEligible subjectsControlled TrialsAtherosclerotic progressionEfficacy measuresMixed hyperlipidemiaTreatment periodOutcome measuresUltrasound studyNumber of subjectsFamilial hypercholesterolemiaCarotid segments
1990
Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty
Young L, Jaffe C, Revkin J, McNulty P, Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. The American Journal Of Cardiology 1990, 65: 986-990. PMID: 2327360, DOI: 10.1016/0002-9149(90)91001-m.Peer-Reviewed Original ResearchConceptsGreat cardiac veinDistal perfusionLactate releaseEjection fractionVentricular functionCardiac veinBalloon inflationLeft ventricular ejection fractionDistal coronary perfusionMyocardial lactate metabolismVentricular ejection fractionMyocardial lactate releaseRegional contractile functionNet lactate extractionNet lactate releaseCoronary angioplastyLeft anteriorCoronary perfusionLactate extractionContractile functionPerfusionAngioplastyLactate concentrationLactate metabolismOxygenated perfluorocarbon